

Han Zhang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6863637/publications.pdf>

Version: 2024-02-01

27
papers

408
citations

840776

11
h-index

794594

19
g-index

27
all docs

27
docs citations

27
times ranked

739
citing authors

#	ARTICLE	IF	CITATIONS
1	Endogenous Endophthalmitis: A 10-year Review of Culture-positive Cases in Northern China. <i>Ocular Immunology and Inflammation</i> , 2010, 18, 133-138.	1.8	46
2	Intravitreal Bevacizumab for Treatment of Subfoveal Idiopathic Choroidal Neovascularization: Results of a 1-Year Prospective Trial. <i>American Journal of Ophthalmology</i> , 2012, 153, 300-306.e1.	3.3	33
3	Effects of the COVID-19 Pandemic on Anti-vascular Endothelial Growth Factor Treatment in China. <i>Frontiers in Medicine</i> , 2020, 7, 576275.	2.6	31
4	The COX-2-Selective Antagonist (NS-398) Inhibits Choroidal Neovascularization and Subretinal Fibrosis. <i>PLoS ONE</i> , 2016, 11, e0146808.	2.5	30
5	Development of a New Mouse Model of Branch Retinal Vein Occlusion and Retinal Neovascularization. <i>Japanese Journal of Ophthalmology</i> , 2007, 51, 251-257.	1.9	29
6	Intravitreal Bevacizumab for Treatment of Macular Edema Secondary to Central Retinal Vein Occlusion: Eighteen-Month Results of a Prospective Trial. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2011, 27, 615-621.	1.4	28
7	INTRAVITREAL BEVACIZUMAB AS PRIMARY TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO PUNCTATE INNER CHOROIDOPATHY. <i>Retina</i> , 2012, 32, 1106-1113.	1.7	28
8	A Novel Platelet-Activating Factor Receptor Antagonist Inhibits Choroidal Neovascularization and Subretinal Fibrosis. <i>PLoS ONE</i> , 2013, 8, e68173.	2.5	27
9	Transforming growth factor- β 2 neutralizing antibodies inhibit subretinal fibrosis in a mouse model. <i>International Journal of Ophthalmology</i> , 2012, 5, 307-11.	1.1	23
10	Increased Nitric Oxide and Vascular Endothelial Growth Factor Levels in the Aqueous Humor of Patients with Coats' Disease. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2012, 28, 397-401.	1.4	17
11	Interleukin-6 receptor blockade suppresses subretinal fibrosis in a mouse model. <i>International Journal of Ophthalmology</i> , 2014, 7, 194-7.	1.1	15
12	Protocol of global incidence and progression of age-related macular degeneration. <i>Medicine (United States)</i> , 2016, 95, e4905.	1.0	9
13	Bevacizumab vs ranibizumab for neovascular age-related macular degeneration in Chinese patients. <i>International Journal of Ophthalmology</i> , 2013, 6, 169-73.	1.1	10
14	Prevalence and causes of low vision and blindness in Baotou. <i>Medicine (United States)</i> , 2016, 95, e4905.	1.0	9
15	Incidence of Charles Bonnet syndrome after intravitreal bevacizumab injection in neovascular age-related macular degeneration. <i>Acta Ophthalmologica</i> , 2012, 90, e647-8.	1.1	8
16	Conbercept and Ranibizumab Pretreatments in Vitrectomy with Silicone Oil Infusion for Severe Diabetic Retinopathy. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2019, 35, 161-167.	1.4	8
17	Interleukin-13 and age-related macular degeneration. <i>International Journal of Ophthalmology</i> , 2017, 10, 535-540.	1.1	8
18	Outcomes of Eyes Lost to Follow-Up in Patients with Central Retinal Vein Occlusion Who are Receiving Anti-Vascular Endothelial Growth Factor Treatment. <i>Therapeutics and Clinical Risk Management</i> , 2021, Volume 17, 489-496.	2.0	7

#	ARTICLE	IF	CITATIONS
19	Blindness, low vision and cataract surgery outcome among adults in Hohhot of Inner Mongolia: a Rapid Assessment of Avoidable Blindness (RAAB) study. <i>British Journal of Ophthalmology</i> , 2018, 102, 1653-1657.	3.9	6
20	AQUEOUS HUMOR CYTOKINE LEVELS AND REBOUND MACULAR EDEMA AFTER CONBERCEPT TREATMENT IN PATIENTS WITH CENTRAL RETINAL VEIN OCCLUSION. <i>Retina</i> , 2021, 41, 834-843.	1.7	6
21	Top 100 cited articles in ophthalmic epidemiology between 2006 and 2016. <i>International Journal of Ophthalmology</i> , 2018, 11, 1994-1998.	1.1	6
22	Clinical Features of Central Retinal Vein Occlusion in Young Patients. <i>Ophthalmology and Therapy</i> , 2022, 11, 1409-1422.	2.3	6
23	Correlations among peripapillary vasculature, macular superficial capillaries, and eye structure in healthy and myopic eyes of Chinese young adults (STROBE). <i>Medicine (United States)</i> , 2020, 99, e22171.	1.0	5
24	Antiangiogenic immunotherapy targeting Flk-1, DNA vaccine and adoptive T cell transfer, inhibits ocular neovascularization. <i>Biochemical and Biophysical Research Communications</i> , 2009, 381, 471-476.	2.1	3
25	Assessment of conbercept therapy for high myopia macular neovascularization by optical coherence tomography angiography. <i>Scientific Reports</i> , 2020, 10, 16959.	3.3	3
26	<p>Effect of Platelet-Activating Factor on Barrier Function of ARPE-19 Cells</p>. <i>Drug Design, Development and Therapy</i> , 2020, Volume 14, 4205-4214.	4.3	3
27	Comparison of the Effect of Intravitreal Conbercept and Ranibizumab on Aqueous Humor Cytokines in Central Retinal Vein Occlusion-Related Macular Edema. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2021, 37, 52-59.	1.4	2